Table 2.
Results of immunohistochemistry for 279 study participants
| Marker | No staining | Weak staining | Strong staining | Missing | ||||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | |
| COX-2: normal | 50 | 18% | 45 | 16% | 78 | 28% | 106 | 38% |
| COX-2: tumor | 42 | 15% | 40 | 14% | 75 | 27% | 122 | 44% |
| TGF-β: normal a | 27 | 10% | 42 | 15% | 15 | 5% | 195 | 70% |
| TGF-β: tumor | 94 | 12% | 68 | 34% | 85 | 24% | 32 | 30% |
| TNF-α: normal a | 28 | 10% | 43 | 15% | 7 | 3% | 201 | 72% |
| TNF-α: tumor | 54 | 19% | 99 | 36% | 41 | 15% | 85 | 30% |
| Vimentin: normal | 50 | 18% | 145 | 52% | 33 | 12% | 51 | 18% |
| Vimentin: tumor | 47 | 17% | 82 | 30% | 121 | 43% | 29 | 10% |
| IGF-1R: normal a | 25 | 9% | 3 | 1% | 10 | 4% | 241 | 86% |
| IGF-1R: tumor | 69 | 25% | 58 | 21% | 73 | 26% | 79 | 28% |
| IGFBP-2: normal a | 8 | 3% | 2 | 1% | 6 | 2% | 263 | 94% |
| IGFBP-2: tumor | 51 | 18% | 67 | 24% | 66 | 24% | 95 | 34% |
a These markers were not analyzed in relation to mammographic density because the proportion missing was > 50%